
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences has demonstrated a strong commitment to advancing its oncology-focused precision medicine portfolio, particularly with darovasertib, which has shown promising efficacy and safety in early and ongoing clinical trials. The company is in the midst of two Phase 3 trials while also pushing forward with multiple catalysts that could enhance its revenue potential, projected to reach approximately $3.2 billion from its leading assets. With compelling data evidencing significant patient improvement and a favorable risk-adjusted probability of success, IDEAYA’s strategic initiatives position it for substantial growth in a high-value sector.
Bears say
IDEAYA Biosciences faces significant financial uncertainties due to unpredictability in future revenues and expenses alongside its non-revenue-generating status, leading to stock price volatility that may not align with current valuations. Potential negative outcomes from clinical trials, such as disappointing readouts and slower enrollment, could hinder commercialization efforts and reduce the market potential of its product candidates like IDE397 and IDE849. Furthermore, challenges regarding intellectual property protection and unclear pathways to commercialization create additional risks that may diminish investor confidence and hinder the company’s competitive positioning in the oncology market.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares